MDL 29951|cas 130798-51-5|DC Chemicals

Cas No.:	130798-51-5
Chemical Name:	3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid
Synonyms:	3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid;MDL-29951;2-Carboxy-4,6-dichloro-1H-indole-3-propionic acid;MDL 29951;1lev;3-(2-Carboxy-4,6-dichloroindol-3-yl)propionic acid;3-(4,6-dichloro-2-carboxyindol-3-yl)propionic acid;2-Carboxy-4,6-dichloro-1H-indole-3-propanoic acid;MDL-29951 2-Carboxy-4,6-dichloro-1H-indole-3-propanoic acid
SMILES:	O=C(O)CCC1=C(C(O)=O)NC2=C1C(Cl)=CC(Cl)=C2
Formula:	C₁₂NO₄Cl₂H₉
M.Wt:	302.1102
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with Ki of 0.14 μM for [3H]glycine binding in vitro and in vivo.

In Vitro:

MDL 100,748 and MDL 29,951 are approximately 2000-fold selective for the glycine binding site relative to the glutamate recognition sites[1]. MDL-29951 is found to inhibit the human F16Bpase under these conditions (IC50=2.5 μM). MDL-29951 inhibits the human liver (IC50=2.5 μM), porcine kidney (IC50=1.0 μM), and rabbit liver (IC50=0.21 μM) isoforms of the enzyme, but is significantly less potent against the rat liver isoform (IC50=11 μM)[2]. The MDL29951-activated receptor exhibits other activities associated with GPCR-mediated signaling, including G protein-dependent activation of extracellular signal-regulated kinase 1 and 2 (ERK1/2) and recruitment of β-arrestin. As with recombinant cell systems, MDL29951 promotes Ca2+ signaling responses and inhibition of cyclic adenosine monophosphate (cAMP) accumulation in rat oligodendrocyte precursor cells during the period of peak GPR17 abundance. Effects of MDL29951 are markedly reduced in cells with low GPR17 abundance and are blocked by pranlukast[3].

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC8824	Traxoprodil	Traxoprodil is an NMDA ε 2 (NR2B) antagonist that has been studied as an alternative to serotonin selective reuptake inhibitors.
DC7863	Talampanel (GYKI 53773)	Talampanel is a novel anticonvulsant that acts as an allosteric inhibitor of the AMPA receptor.
DC8175	Rapastinel(GLYX-13)	Rapastinel(GLYX-13) is a NMDA receptor partial agonist that acts at the glycine site.
DC8307	QNZ46	QNZ is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively).
DC7226	Perampanel(E2007）	Perampanel(E2007; ER 155055-90) is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials.
DC7989	PEPA	PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity.
DC11382	NYX-2925	NYX-2925 is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.
DC7576	NVP-AAM077	NVP-AAM077 is a potent antagonist for NMDA receptors.
DC11406	NBQX	NBQX is a potent aminomethylphosphonic acid receptor (AMPAR) antagonist with an IC50 of 0.7 ± 0.1 μM.
DC7194	MDL 29951	MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.